ArticleEBioMedicine2026

Targeting pyruvate kinase M2 (PKM2) reduces T cell pathogenicity in multiple sclerosis.

Elena Ellmeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.